Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637528 | 0.86 | KCNH2 (0.56) | MEN1KMT2AALDH1A1SCN9AKCNH2 | |
| SCHEMBL3585037 | 0.86 | KCNH2 (0.56) | MEN1KMT2AALDH1A1SCN9AKCNH2 | |
| SCHEMBL4637526 | 0.86 | KCNH2 (0.56) | MEN1KMT2AALDH1A1SCN9AKCNH2 | |
| SCHEMBL2350627 | 0.86 | KCNH2 (0.56) | MEN1KMT2AALDH1A1SCN9AKCNH2 | |
| SCHEMBL3585032 | 0.86 | KCNH2 (0.56) | MEN1KMT2AALDH1A1SCN9AKCNH2 | |
| SCHEMBL3600447 | 0.86 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1MAPTTP53 | |
| SCHEMBL3600450 | 0.86 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1MAPTTP53 | |
| SCHEMBL28521573 | 0.86 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1MAPTTP53 | |
| SCHEMBL15832346 | 0.85 | TSHR (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28527166 | 0.85 | L3MBTL1 (0.49) | MEN1KMT2AALDH1A1POLBSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125829-B1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8008293-B2 | Bicyclic oxomorpholine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2125829-A2 | BICYCLIC OXOMORPHOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008108378-A2 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-12 | — | — | WO | disclosed |
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | OPRM1, OPRK1, OPRD1 | MEN1 1788/4885KMT2A 4441/4885ABCC1 1143/4885 |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | OPRM1, OPRK1, OPRD1 | MEN1 1670/4885KMT2A 2870/4885ABCC1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.